Cancel
GentiBio
GentiBio Employees
58 people indexed:
-
s6f8.z3fws472q@pv5k8278.90f Sign up to see email
-
v49w4j.76kdkj8@z4k2ky07.jqz Sign up to see email
-
Alberto del Rio Espinola
Director, Translational Sciences
2y796f9.2kq.w2z.4vxq3h7x@740z0qxj.2jf Sign up to see emailyw6hf89.3fh.qzh.76jhvh40@ux817x1j.5yz Sign up to see email -
Alexa Perdikis
Associate Director, Talent Acquisition & Employee Experience
195hv.6wyff757@65947qy3.0f1 Sign up to see email0j786.yv5yh58z@h0z60u88.v2y Sign up to see email -
Andrew Stuart
Principal Development Associate Scientist
yj0j0v.fjllhy@qh12j19v.pl1 Sign up to see emailj6ql27.qp7018@2hp037hl.jyf Sign up to see email -
Andy Tran
Biotech Investor, Matrix Capital Management, Board Director
szws.z67j@5z82lujh.053 Sign up to see emailxj5p.q0kv@837527f5.k0l Sign up to see email -
f79f.u354jp@8vus1pz5.064 Sign up to see email
-
1p01j3.04rf752@f3qfwrq8.k4p Sign up to see email
-
506kl.6zdf10v1@6kf815jf.xvl Sign up to see email
-
juy85.pwz4y0@w023qq30.s6u Sign up to see email
-
Chandra Patel
Co-founder and VP, Research and Development Operations
591u5k3.fuww9@28q9xk0x.0y9 Sign up to see email4kx6zs2.wykfq@q1qs40qs.qq6 Sign up to see email -
22jxk6yvyx8.z.qf994@au9xf7aj.954 Sign up to see email
-
yawp2.3j89w2w5pyd@168avf43.x5z Sign up to see email
-
kuz19.9.lqkf0@k21u3uvd.hhz Sign up to see email
-
3vf37.xpfhhj@q76f7uxf.8vf Sign up to see email
-
5519p.x33h6q@6y78sw14.pql Sign up to see email
-
02rz8a.vsfrkh2szp@vv7rfs2a.af5 Sign up to see email
-
1a1jv.jvz2@kwj5r97x.k10 Sign up to see email
-
Erez Chimovitz
Partner, OrbiMed, Chairman of the Board
kls4.6fk7a6f7y@w8qq81xu.51k Sign up to see email0516.w21351jka@wajj20j6.224 Sign up to see email -
7zdl.7873110@wpk1pzw5.843 Sign up to see email
-
Hadas Weinstein-Marom
Senior Scientist & Lecturer, MIGAL, Scientific Co-Founder
7421v.6x78j098p249lq0@xykqu22y.vq5 Sign up to see emailqkq2p.6lvf3u77u2f75qk@7pqklkpv.445 Sign up to see email -
rzr1j.3u389q@4yp4695x.x6f Sign up to see email
-
k5uw9.z8u016wf@j74x114q.v95 Sign up to see email
-
ydvzv6.p44yq4v@a30523dj.5sa Sign up to see email
-
97fzz.x4lzxzlll@92h9qqxq.8jy Sign up to see email
-
sxk3.hus97hvu6p@k3sz1342.ss7 Sign up to see email
-
q899p313.szv5zh@015v89yd.vpk Sign up to see email
-
k2uvqkp1.9d9@hx2vq55l.485 Sign up to see email
-
69dk.lz39p2@18u28aa3.lxa Sign up to see email
-
086q.418qzuv@6zh43vfq.25j Sign up to see email
-
zf599.8d0j9py@5dd2442l.xr6 Sign up to see email
-
ydp1l7.093djz@q5442u19.3pl Sign up to see email
-
0v8qq6.ujq8@p9r328f1.hk6 Sign up to see email
-
Margaret Readio
Director, Head of Technical Development Operations
zxu2514p.0j3xk6@6l56zpyk.09w Sign up to see emailkkwqy2wj.h375zf@17z3hqj3.k2j Sign up to see email -
xqxvs.178us@69ysqq77.5q7 Sign up to see email
-
k84826y.l60df2fuuk48f@h2h7uwd1.27p Sign up to see email
-
Michal Silverberg
Managing Director, Novartis Venture Fund, Board Director
pj4quz.ujzu07qjzq@40uk4ypq.x20 Sign up to see email6196wp.wdfd4jzd9u@2w2u5414.0p1 Sign up to see email -
Mirna Mujacic
VP, Process and Analytical Development
yf076.4y02sdf@3w7z04d2.kks Sign up to see email46hs4.v21zdsq@4v49w1xd.d0y Sign up to see email -
Nandita Shangari
Managing Director RA Capital, Board Director
z5k269u.jzqzp08z@xqqxv601.w48 Sign up to see email5jy2lwk.xj59109x@01w4x5wj.xlj Sign up to see email -
w1k4uu.zajz@3sh4vau9.a9k Sign up to see email
-
3wr085.y8uqr0@z6ljdu66.zl3 Sign up to see email
-
hwd0q.18jd8@wfkx0628.dhj Sign up to see email
-
jk3f3k.u1fw52@j8893qqy.dj6 Sign up to see email
-
0s5419.xhv3sjw9s1v@817s2vyx.y4y Sign up to see email
-
26j96.zj8635fj.f7542wf@j5z7966j.0x7 Sign up to see email
-
7889j1.9069@qpkuxwu1.pdf Sign up to see email
-
Rebecca Brunette
Associate Director, Product Sciences and Characterization
qh39wl6.2504wp29@wdslxh84.5y7 Sign up to see emaill46z5x7.sszy51l0@yh2jlqlq.xwz Sign up to see email -
zx7.vz81j2puh@1125s13w.uwk Sign up to see email
-
52jq.32z97@vwqp92qv.a64 Sign up to see email
-
731pq.4pzzv2y51@78fq9ywz.d0j Sign up to see email
-
Scott Hussell
Senior Scientist, Analytical Development
jz49w.57zapfv@64yar554.7zv Sign up to see emailw479v.jw0p98f@qp30q1w6.d11 Sign up to see email -
14wf9uy.27yzj@26wuzfxf.0uf Sign up to see email
-
43p2zx6.4v84@p1d4xzu7.9dd Sign up to see email
-
rww.98w@waz7wpl0.k74 Sign up to see email
-
Tom Crevier
Senior Director, Automation, Informatics, and IT
h3y.jfahwx3@57uylqfs.3a1 Sign up to see emailj0u.j872ssw@p9hp43yp.4l0 Sign up to see email -
upj.xyq353j@suuvjv27.7zq Sign up to see email
-
1h6419q.9f.95179@95990wkl.h13 Sign up to see email
-
0f1qfyh7.sss34ff@hyz89x36.ww7 Sign up to see email
GentiBio Company Information
GentiBio is a biotechnology firm that specializes in creating engineered T regulatory (Treg) cell therapies aimed at treating autoimmune, auto-inflammatory, alloimmune, and allergic diseases. Their lead candidate, GNTI-122, is an autologous engineered Treg product specifically designed for the treatment of type 1 diabetes. GentiBio’s approach involves a modular engineering platform that enables the creation of optimized Treg phenotypes tailored to address specific diseases. This platform addresses major challenges in Treg therapeutics, including scalable engineering, tissue targeting, and specific IL-2 signaling support. The company has secured significant financial backing, raising $157 million in Series A financing and launching with an initial $20 million seed funding from notable investors such as OrbiMed, Novartis Venture Fund, and RA Capital Management. Additionally, GentiBio is collaborating with Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases. The company has also been recognized as one of BioSpace’s 2023 Best Places to Work.
Report inaccurate information
Report inaccurate information
